GeoVax to Present Data on GEO-CM04S1, A Next Generation Covid-19 Vaccine, at the World Vaccine Congress

​​ATLANTA, GA – (NewMediaWire) – March 28, 2024 – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that its Chief Scientific Officer, Mark Newman, PhD, will present data on GEO-CM04S1, the Company’s next-generation Covid-19 vaccine candidate, during the upcoming 24th Annual World Vaccine Congress taking place in Washington, DC on April 1-4, 2024. Presentation Details:Presenter:                 Mark Newman, PhD, Chief Scientific OfficerDate/Time:               Thursday, April 4, 2024, 12:00 pm ETLocation:                  Walter E. Washington Convention Center, Washington, DCPresentation Title:     Vaccine Induction of Broadly-Specific Antibody and T Cell Responses to CombatSARS-CoV-2 Variation Dr. Newman’s presentation will focus on results delineating the unique immune system driven mechanisms that contribute to the broad efficacy of GeoVax’s next-generation Covid-19 vaccine, GEO-CM04S1. About GEO-CM04S1GEO-CM04S1 is based on GeoVax’s MVA viral vector platform, which supports the presentation of multiple vaccine antigens to the immune system in a single dose. GEO-CM04S1 encodes for both the spike (S) and nucleocapsid (N) antigens of SARS-CoV-2 and is specifically designed to induce both antibody and T cell responses to those parts of the virus less likely to mutate over time. The more broadly functional engagement of the immune system is designed to protect against severe disease caused by continually emerging variants of Covid-19. Vaccines of this format should not require frequent and repeated modification or updating. GEO-CM04S1 is currently being evaluated in three ongoing Phase 2 clinical trials:·       As a primary vaccine in immunocompromised patients (with hematologic cancers receiving cell transplants or CAR-T therapy). ClinicalTrials.gov Identifier: NCT04977024. A recent presentation of unpublished data from the open-label portion of the trial indicates that GEO-CM04S1 is highly immunogenic in these patients, inducing both antibody responses, including neutralizing antibodies, and T cell responses.·       As a booster vaccine in immunocompromised patients with chronic lymphocytic leukemia (CLL), a recognized high-risk group for whom current mRNA vaccines and monoclonal antibody (MAb) therapies appear inadequate relative to providing protective immunity. ClinicalTrials.gov Identifier: NCT05672355.·       As a booster vaccine for healthy patients who have previously received the Pfizer or Moderna mRNA vaccine. This trial was fully enrolled in September 2023 and final results are expected in Fourth Quarter 2024, reflecting a 12-month tracking of study patients.  ClinicalTrials.gov Identifier: NCT04639466. About GeoVax GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel therapies and vaccines for solid tumor cancers and many of the world’s most threatening infectious diseases. The company’s lead program in oncology is a novel oncolytic solid tumor gene-directed therapy, Gedeptin®, presently in a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. GeoVax’s lead infectious disease candidate is GEO-CM04S1, a next-generation Covid-19 vaccine targeting high-risk immunocompromised patient populations. Currently in three Phase 2 clinical trials, GEO-CM04S1 is being evaluated as a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized Covid-19 vaccines are insufficient, and as a booster vaccine in patients with chronic lymphocytic leukemia (CLL). In addition, GEO-CM04S1 is in a Phase 2 clinical trial evaluating the vaccine as a more robust, durable Covid-19 booster among healthy patients who previously received the mRNA vaccines. GeoVax has a leadership team who have driven significant value creation across multiple life science companies over the past several decades. For more information, visit our website: www.geovax.com. Forward-Looking Statements This release … 

Related Post
Innovation Newsletter
Don't miss the most important news about Innovation. Sign up to receive them by email.

BlogofInnovation.com  

Innovation Newsletter
Don't miss the most important news about Innovation. Sign up to receive them by email.

Recent Posts

Good heart health in middle age may preserve brain function among Black women as they age

​​Research Highlights: Middle-aged Black women with better heart health were less likely to show a decline in mental function compared…

10 hours ago

Revolutionizing Hydration: Alkaline Ionized Water Takes India by Storm

Alkaline ionized water is being widely used in India, signifying a new phase of hydration for consumers with health concerns.…

22 hours ago

MoogleLabs Newest Feat – AI-powered Offensive Language Detection Tool: SwearSwap

MoogleLabs is an organization that is consistently making waves in the world of AI and technology with its innovative solutions…

22 hours ago

iCoreConnect Inc. Announces New State Endorsement of Seven Solutions From the Tennessee Dental Association

​​New Endorsements Allows iCoreConnect New Entry Into the Tennessee MarketOCOEE, FL - (NewMediaWire) - April 23, 2024 - iCoreConnect Inc. (NASDAQ:…

23 hours ago

Ubiquitech Software Corporation Reports Total Convertible Debt Reduction in Excess of $1,700,000 During Past 12 Months

​​DENVER, CO - (NewMediaWire) - April 23, 2024 - Ubiquitech Software Corp. (OTC: UBQU), a trailblazer in innovative software development, is pleased…

1 day ago

Sunknowledge Celebrates 10 Years of Successful Partnership in Providing Medical DME Billing Solutions to Top DME Company in New York

NEW YORK, N.Y., April 23, 2024 (SEND2PRESS NEWSWIRE) — Sunknowledge, a leading provider of healthcare outsourcing solutions, proudly celebrates a…

1 day ago

Seguici

Innovation Newsletter
Don't miss the most important news about Innovation. Sign up to receive them by email.